0.9501
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World
Plus Therapeutics (NASDAQ:PSTV) Earns “Buy” Rating from D. Boral Capital - Defense World
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com India
Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus
Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Plus Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PLUS THERAPEUTICS Earnings Results: $PSTV Reports Quarterly Earnings - Nasdaq
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Plus Therapeutics Doubles Survival Rates in Brain Cancer Trial, Raises $15M to Accelerate Growth - Stock Titan
A Peek at Plus Therapeutics's Future Earnings - Benzinga
PLUS THERAPEUTICS Earnings Preview: Recent $PSTV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Plus Therapeutics Introduces REYOBIQ - citybiz
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView
Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey
10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com
FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa
Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks
FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India
Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan
Plus Therapeutics Sets Earnings Date: CNS Cancer Drug Developer to Report Q4 Results - StockTitan
Plus Therapeutics, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Plus Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Now Covered by Analysts at D. Boral Capital - Defense World
Plus Therapeutics stock gains on Boral Capital Buy rating By Investing.com - Investing.com South Africa
Plus Therapeutics stock gains on Boral Capital Buy rating - Investing.com India
D. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy Recommendation - Nasdaq
Plus Therapeutics initiated with a Buy at D. Boral Capital - TipRanks
Plus Therapeutics regains compliance with Nasdaq minimum stockholders’ equity requirement - MSN
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph
Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan
Plus Therapeutics Regains Nasdaq Compliance - Nasdaq
Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia
Plus Therapeutics regains Nasdaq compliance - Investing.com India
SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow
Plus Therapeutics regains Nasdaq compliance status - Investing.com India
Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):